The test uses blood samples to diagnose breast and colon cancers.
Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company InCure Ltd. reports positive results in the clinical trial for its device, which uses blood samples to diagnose breast and colon cancers.
InCure's diagnostic test was able to distinguish between healthy women and those with cancer with a statistically significant success rate. The diagnostic test can discover the presence of tumors at very early stages, when they comprise only a few cells, which pass in the blood stream. Diagnosis at this stage makes it possible to know whether focused treatment is sufficient, or if system treatment is necessary.
On the basis of the trial results, InCure has begun preliminary negotiations with an international company that specializes in developing commercial diagnostic kits. This company will also market InCure's products after development, and will be responsible for regulatory procedures.
Hadasit Bio owns 75% of InCure. Its share rose 3.6% yesterday on the news.
Published by Globes [online], Israel business news - www.globes-online.com - on November 21, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007